Santarus and VeroScience announced the inclusion of Cycloset (bromocriptine mesylate) as a therapy for patients with type 2 diabetes in a new diabetes management algorithm published by the American Association of Clinical Endocrinologists (AACE).

Cycloset is a dopamine agonist (ergot derivative) currently indicated as adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

The AACE algorithm supports the use of Cycloset for the following:

  • In patients with entry HbA1c >7.5%, the algorithm recommends dual therapy to include Cycloset as one option in combination with metformin or another first-line agent.
  • In patients that need triple therapy and for those patients without symptoms that present with an HbA1c >9.0%.

In a matrix that profiles attributes of several antidiabetic medications, Cycloset received a “neutral” rating for hypoglycemia, weight gain, renal function, CHF, and bone loss, and received a “moderate” rating for GI effects.

For more information call (904) 353-7878 or visit the Cycloset website